Printer Friendly

The Immune Response Corporation Publishes Additional Findings On T Cells Involved in Psoriasis

CARLSBAD, Calif., July 9 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today announced the publication of additional findings supporting its discovery of specific T cells in psoriatic lesions. These findings, published in the June 1997 edition of the Archives of Dermatology, support the company's earlier findings published in September 1994 in The Proceedings of the National Academy of Sciences.

The company first discovered two populations of T cells, VB3 and VB13.1, in skin lesions from psoriasis patients. In the first publication, five of seven patients had elevated levels of these T cells in psoriatic lesions. Additional research leading to the current publication demonstrated that among nine new patients, eight had an elevated level of VB3 and/or VB13.1 T cells in their psoriatic lesions. These specific T cells persist in psoriasis patients and were found in repeated biopsies, taken at varying intervals of as much as 15 months apart.

Combining the results of both studies, 81% of patients studied (13 of 16) had elevated levels of VB3 and/or VB13.1. The company is developing its T cell receptor peptide vaccine technology to reduce the number of these specific T cells as a treatment for psoriasis. The company intends to begin a Phase II clinical trial by year-end 1997 using a T cell receptor peptide vaccine consisting of VB3 and VB13.1 peptides.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, with technologies in four core areas: HIV, autoimmune disease, gene therapy and cancer. The company is conducting clinical trials using immune-based therapies for HIV, psoriasis, rheumatoid arthritis, multiple sclerosis, colon cancer and brain cancer, and preclinical studies for prostate cancer. The company is also developing gene therapy treatments for cardiovascular disease, hemophilia and hepatitis.

This news release contains forward-looking statements. Actual results could vary from those expected due to a variety of risk factors, including the uncertainty of confirmation of the research findings discussed above, whether any potential therapeutic vaccine will be shown to be safe and efficacious in clinical trials, and those risk factors set forth from time to time in The Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1996. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE Immune Response Corporation
 -0- 07/09/97


/NOTE TO EDITORS: The Immune Response Corporation news releases are available at no charge through PR Newswire's Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com/

/CONTACT: Debra L. Altman, Investor Relations for The Immune Response Corporation, 760-431-7080/

(IMNR)

CO: Immune Response Corporation ST: California IN: MTC SU: PDT

ML-CW -- LAW016 -- 8330 07/09/97 08:16 EDT http://www.prnewswire.com
COPYRIGHT 1997 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 9, 1997
Words:522
Previous Article:American Pacific Corporation Appoints John R. Gibson Chief Executive Officer
Next Article:Oprah's First-Ever Home Video Premieres September 30 From Buena Vista Home Video; Oprah's Proceeds From the Video Go to Charity
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters